ConductScience.org, home

Paper39172012

TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.

Kortleve D and 20 others. Cancer Discov, 2024. Cited by 15 papers, by iCite.

Cite this record

ConductScience Library. TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer. Papers, record 39172012. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39172012

Download JSON
Cell line
HEK293T2,726 papers
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
TCR-Engineered T Cells Directed against Ropporin-1 Constitute a Safe and Effective Treatment for Triple-Negative Breast Cancer.
PubMed
Journal
Cancer Discov
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
15
iCite
Relative citation ratio, by iCite
1.62, provisional
iCite
Revised in PubMed
2024-12-04
PubMed

Authors21

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Triple Negative Breast NeoplasmsMajor topic
Receptors, Antigen, T-CellMajor topic
Humans
Female
Animals
T-Lymphocytes
Mice
Cell Line, Tumor
Xenograft Model Antitumor Assays

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
EMC-TKI LSH20020Health∼Holland (LSH)PubMed
n/aErasmus MC Daniel den Hoed FoundationPubMed
2014-7087KWF Kankerbestrijding (DCS)PubMed

Source PubMed

Download CSV of grants

References99

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
121130497Real time detection of peptide-MHC dissociation reveals that improvement of primary MHC-binding residues can have a minimal, or no, effect on stability.Mol Immunol2011https://conductscience.org/library/papers/21130497PubMed
219451549Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen.Blood2009https://conductscience.org/library/papers/19451549PubMed
325414323Allele frequency net 2015 update: new features for HLA epitopes, KIR and disease and HLA adverse drug reaction associations.Nucleic Acids Res2015https://conductscience.org/library/papers/25414323PubMed
423423337Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.Mol Ther2013https://conductscience.org/library/papers/23423337PubMed
510602881SYFPEITHI: database for MHC ligands and peptide motifs.Immunogenetics1999https://conductscience.org/library/papers/10602881PubMed
627869121Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry.Nat Commun2016https://conductscience.org/library/papers/27869121PubMed
727558661Prognostic significance of nuclear expression of UMP-CMP kinase in triple negative breast cancer patients.Sci Rep2016https://conductscience.org/library/papers/27558661PubMed
827765921Triple-negative breast cancer: is there a treatment on the horizon?Oncotarget2017https://conductscience.org/library/papers/27765921PubMed
99679755Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer.Int J Cancer1998https://conductscience.org/library/papers/9679755PubMed
1029282079Expitope 2.0: a tool to assess immunotherapeutic antigens for their potential cross-reactivity against naturally expressed proteins in human tissues.BMC Cancer2017https://conductscience.org/library/papers/29282079PubMed
1112175724Prediction of MHC class I binding peptides using profile motifs.Hum Immunol2002https://conductscience.org/library/papers/12175724PubMed
1223601657miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.Breast Cancer Res2013https://conductscience.org/library/papers/23601657PubMed
1324518294β1 integrin inhibition elicits a prometastatic switch through the TGFβ-miR-200-ZEB network in E-cadherin-positive triple-negative breast cancer.Sci Signal2014https://conductscience.org/library/papers/24518294PubMed
1428366766Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.Mol Ther2017https://conductscience.org/library/papers/28366766PubMed
1515496961Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.Gene Ther2005https://conductscience.org/library/papers/15496961PubMed
1629929481Gene length corrected trimmed mean of M-values (GeTMM) processing of RNA-seq data performs similarly in intersample analyses while improving intrasample comparisons.BMC Bioinformatics2018https://conductscience.org/library/papers/29929481PubMed
1725613900Proteomics. Tissue-based map of the human proteome.Science2015https://conductscience.org/library/papers/25613900PubMed
1822400038TCR gene transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 epitopes as melanoma-specific immune targets.Clin Dev Immunol2012https://conductscience.org/library/papers/22400038PubMed
1916282986Phoenix-ampho outperforms PG13 as retroviral packaging cells to transduce human T cells with tumor-specific receptors: implications for clinical immunogene therapy of cancer.Cancer Gene Ther2006https://conductscience.org/library/papers/16282986PubMed
2036185575Immunopeptidome of hepatocytes isolated from patients with HBV infection and hepatocellular carcinoma.JHEP Rep2022https://conductscience.org/library/papers/36185575PubMed

See all 99 referencesDownload CSV of references

Cited by10

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 15 citations.

PMIDTitleJournalYearIn PapersSource
42321956Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.Exp Hematol Oncol2026https://conductscience.org/library/papers/42321956PubMed
42120393Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.NPJ Breast Cancer2026https://conductscience.org/library/papers/42120393PubMed
41948334Targeting the tripartite axis of immune-metabolic-spatial crosstalk to overcome therapy resistance in breast cancer.Front Immunol2026https://conductscience.org/library/papers/41948334PubMed
41943836In vivo CRISPR/Cas9 Screening Reveals that UBE2L3 Modulates Autophagic Flux through TSC2 Ubiquitination and Potentiates PD-1 Blockade in Triple-Negative Breast Cancer.Int J Biol Sci2026https://conductscience.org/library/papers/41943836PubMed
41899515Immunotherapies for Breast Cancer: From Checkpoint Inhibition to Emerging Cellular Therapies.Cancers (Basel)2026https://conductscience.org/library/papers/41899515PubMed
41039188Programmed cell death in triple-negative breast cancer.Cell Mol Biol Lett2025https://conductscience.org/library/papers/41039188PubMed
41007774Neoantigen-Driven Immunotherapy in Triple-Negative Breast Cancer: Emerging Strategies and Clinical Potential.Biomedicines2025https://conductscience.org/library/papers/41007774PubMed
40904610ROPN1 Gene Expression as a Prognostic and Predictive Biomarker in Aggressive Breast Cancer: Clinical Implications and Survival Association.Eur J Breast Health2025https://conductscience.org/library/papers/40904610PubMed
40730190Tumor-specific CD8 T cell characterization in HR+ breast cancer reveals an impaired antitumoral response in patients with lymph node metastasis.Cell Rep Med2025https://conductscience.org/library/papers/40730190PubMed
40178291CD3xHER2 bsAb-Mediated Activation of Resting T-cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFNγ and TNFα.Eur J Immunol2025https://conductscience.org/library/papers/40178291PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
ROPN154763PubTator's text mininghttps://conductscience.org/library/genes/54763NCBI Gene
TRBV20OR9-26962PubTator's text mininghttps://conductscience.org/library/genes/6962NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39172012

GET https://conductscience.org/api/papers/v1/39172012/authors?page=2